224 documents

Read All
11:39 , Dec 1, 2016 |  BC Week In Review  |  Clinical News

Xiaflex: Ph IIa data

A double-blind, U.S. and Australian Phase IIa trial in 75 patients with Dupuytren’s disease and ≥1 palmar nodule showed that a single injection of Xiaflex significantly reduced mean nodule surface area, consistency score and hardness...
Read More
07:00 , Jun 29, 2015 |  BioCentury  |  Finance

Arch's golden returns

Mid-month SEC filings show Arch Venture Partners has used two companies with roaring stock prices - Agios Pharmaceuticals Inc. (NASDAQ:AGIO) and Receptos Inc. (NASDAQ:RCPT) - to completely pay back LPs in its $400 million seventh...
Read More
07:00 , Sep 1, 2014 |  BC Week In Review  |  Clinical News

Xiaflex: Phase II started

BioSpecifics Technologies started a double-blind, U.S. Phase II trial of Xiaflex in 20 adult patients with >=2 benign lipomas of similar size. Patients will have 1 lipoma treated with Xiaflex, while the other will receive...
Read More
07:00 , Apr 10, 2014 |  BC Innovations  |  Tools & Techniques

Toxic assets

A new tool for in vivo detection of liver toxicity could represent a significant improvement over routine methods that only work in vitro or on tissue slices. 1 The litmus test for the Stanford University...
Read More
08:00 , Jan 13, 2014 |  BC Week In Review  |  Clinical News

Xiaflex collagenase clostridium histolyticum: Phase II data

Top-line data from an open-label, dose-escalation, U.S. Phase II trial in 14 lipoma patients showed that a single injection of Xiaflex met the primary endpoint of actively reducing the visible surface area of the lipoma...
Read More
08:00 , Jan 7, 2013 |  BC Week In Review  |  Clinical News

Cavatak: Interim Phase II data

Interim data from 13 evaluable patients with stage IIIc/IV malignant melanoma in the first stage of a 2-stage, open-label, U.S. Phase II trial showed that 10 intratumoral injections of Cavatak produced 3 objective responses defined...
Read More
08:00 , Dec 5, 2011 |  BC Week In Review  |  Company News

PerkinElmer sales and marketing update

PerkinElmer's Caliper company launched Vectra 2 with AQUA technology in North America, Asia and Europe. Caliper partnered with HistoRx Inc. (New Haven, Conn.) in March to develop the immuno-fluorescence imaging technology to measure proteins in...
Read More
08:00 , Nov 14, 2011 |  BC Week In Review  |  Company News

Caliper, PerkinElmer deal

PerkinElmer completed its acquisition of fellow life sciences supply company Caliper for $10.50 per share, or about $600 million in cash (see BioCentury, Sept. 12). Caliper Life Sciences Inc. , Hopkinton, Mass.   PerkinElmer Inc....
Read More
07:00 , Oct 31, 2011 |  BC Week In Review  |  Company News

Caliper, DxTerity Diagnostics deal

The companies will partner to co-develop and co-market DxTerity's NEAT multiplex diagnostic assays on Caliper's LabChip Dx platform worldwide. The NEAT assay detects SNPs from blood or formalin-fixed paraffin-embedded (FFPE) tissue samples, while the LabChip...
Read More
07:00 , Oct 3, 2011 |  BioCentury  |  Finance

Cost averaging down

Even the best fundamentals may not be able to overcome the negative effects of the broader economy on the stock market this quarter. As a result, specialists have little hope of major gains and instead...
Read More